SAR-FUSION

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameSAR-FUSION
Drug Alias NameFsn-0503cathepsin S targeting mAb (Fusion)Fsn-0503hSAR-FUSION
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCathepsins inhibitors
TargetsCathepsins
Therapy Area/IndicationsColorectal NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New ZealandUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFusion Antibodies
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFusion AntibodiesClarity Pharmaceuticals LtdFusion Pharma Llc
Active IndicationsN/A
Inactive IndicationsColorectal NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A